(Globe Newswire) San Diego and Toronto — StateHouse Holdings Inc., a California-focused, vertically integrated cannabis company, announced that members of its management team are participating in the following upcoming industry conferences:
—The Cannabis Science Conference held on September 20-22, 2023, in Providence, Rhode Island. Travis Higginbotham, Vice-President of Cultivation at StateHouse, presented on a study entitled “The Impact of Light Distribution on Cannabis Sativa: Intercanopy vs Overhead Light with Equal DLIs.”
—The Benzinga Cannabis Capital Conference is being held on September 27-28, 2023, in Chicago, Illinois. Ed Schmults, chief executive officer of StateHouse, will participate in a panel entitled “The State of California Retail” on Wednesday, September 27 at 1:00 PM CST. Additionally, management will host a series of one-on-one meetings throughout the conference.
Change of Auditor
Advertisement
On September 21, 2023, the company’s auditor Armanino LLP resigned in conjunction with its decision to discontinue providing services to public companies. The resignation does not reflect concerns with StateHouse specifically or regarding the cannabis industry in general.
The company has commenced a selection process for a successor auditor and will inform the market with a further press release once a candidate has been confirmed. The former auditor will participate in the orderly transition to the successor auditor upon appointment.
The company confirms there were no “reportable events” under National Instrument 51-102: Continuous Disclosure Obligations (NI 51-102) between the company and the former auditor. In Accordance with NI 51-102, the company’s notice of change of auditor and any required associated documentation will be filed on SEDAR in due course.
Activists in Nebraska have initiated a fundraising campaign to garner support for the inclusion of two medical cannabis legalization proposals on the state’s 2024 ballot. The group, Nebraskans for Medical Cannabis (NMM), has already begun the circulation of petitions and claims to have satisfied signature requirements in two counties by the end of last month.
The recent launch event held in Lincoln aimed to address a significant hurdle faced last year: the loss of vital funding after a major donor’s tragic death in a plane crash.
This is the third attempt by NMM to present the reform proposal to voters, and activists maintain their optimism, believing they will secure the necessary grassroots backing and resources to succeed this time around.
The launch showcased the involvement of various caregivers, patients and activists in medical marijuana advocacy, including key figures such as Crista Eggers, the campaign manager, and Senator Anna Wishart and former Senator Adam Morfeld, both of whom cochair NMM.
The campaign is set to obtain signatures from at least 5% of registered voters in 38 counties by year-end, with two counties already accomplished. To secure a place on the November 2024 ballot, the campaign must collect approximately 87,000 valid signatures from registered voters for each petition, in addition to meeting the county-specific goals, by July 5, 2024.
One of the initiatives seeks to establish safeguards for doctors recommending cannabis and patients purchasing and possessing it, effectively creating qualified immunity. The second initiative plans to establish a state cannabis commission to oversee the registration and regulation of individuals involved in the production, distribution and dispensing of medical cannabis.
Governor Jim Pillen has voiced opposition to marijuana reform, asserting that medical cannabis should only be accessible through FDA-approved processes, citing potential risks to children. In contrast, Eggers, NMM’s campaign manager, is determined to advocate for children such as her son, who suffers from severe seizures and could benefit from medical cannabis.
NMM initially submitted its reform petitions in May, with signature collection starting in July. An earlier campaign secured enough signatures for the 2020 ballot but was invalidated by the state Supreme Court due to a single-subject challenge. Subsequently, the revised petitions fell short due to a lack of funding following the tragic plane crash that claimed a key donor’s life.
Efforts by Nebraska legislators, including Wishart, to enact marijuana reform legislatively have consistently faced hurdles in the conservative legislature. Despite receiving a hearing in the unicameral Judiciary Committee in February, Wishart’s medical marijuana bill did not progress, which she attributed to changes in committee membership. A prior version of the measure faced a filibuster and ultimately stalled in the GOP-controlled legislature.
As many more states and countries work to ease their marijuana regulations, companies such as SNDL Inc. (NASDAQ: SNDL) will have a bigger pool of potential markets into which to expand as they grow their footprints.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
Mulching is one of the best things you can do for your garden! An essential component of regenerative-organic and permaculture practices, mulch prevents erosion and helps maintain soil temperature and moisture levels. It also releases nutrients into the ground as it decomposes and prevents weeds from taking over the garden bed. You don’t have to spend much money on mulch; you can find plenty of natural materials near home!
When To Mulch
A good rule of thumb in today’s climate-wise garden is if you see some bare soil, cover it ASAP.
Most gardeners typically apply mulch to the garden every spring to keep the garden cool and moist throughout the heat of the summer. But I also recommend putting some down in the fall, especially if you live in a colder climate.
Mulching the garden in the fall will help insulate plant roots and precious soil life from the cold.
As the mulch breaks down under the snow, it’ll enrich the soil and give your plants the extra boost they need in the spring.
How To Mulch
Mulching is an easy garden chore that will save you work down the line. Less weeding, watering, and worrying about your plant babies!
Spread a two to three-inch layer of your selected material throughout the garden. Do not push the mulch right up around the stems or trunks! It’s best to keep a mulch-free zone of about three inches around the base of the plant.
If you’re mulching bare soil in the summer, water first and then mulch over top. Watering first is unnecessary in the fall or spring, as these are typically wet seasons.
Finally, Mulch Materials
Consider a forest floor; all those natural materials help the trees grow, and they’ll do the same for the garden. Many garden centers sell dyed wood chips, but these won’t do in an organic garden.
. Excellent eco-friendly mulch materials include:
Wood chips
Compost
Low growing groundcovers
Pine needles
Leaf mold
Grass clippings
Cardboard and newspaper
Seaweed
Straw
Corn husks and silks
Rocks (although these won’t offer the soil any nutrients!)
We recently received truckloads of shredded natural tree bark after a terrible storm ripped through our area. If this ever happens in your neighborhood (and I hope it doesn’t!), check with local officials to see if they’ll collect fallen trees and mulch them for the community to use at home.
Mulching is easy, budget-friendly, and great for plants and the environment. It’s one of the cornerstones of permaculture and regenerative agriculture and something no garden should go without!
Health Canada invites current and prospective cannabis licence holders and other interested parties from Black and other racialized communities to participate in a Q&A session on cannabis licensing, compliance and inspections, scheduled for September 28, 2023.
The Victoria Cannabis Co. received more coverage this week for its farmgate application. The micro producer hopes to have their Producer Retail Store licence soon and to be open in the coming months.
Vernon, BC, residentscontinue to complain about odours from a local cannabis facility.
Grodan and F1SeedTech say they have joined forces to conduct cannabis cultivation research at CRIC Labs in Montreal. These new trials will build upon a study conducted at Wageningen University & Research (WUR) in the Netherlands.
Financial services platform Square has entered Canada’s cannabis market in partnership with Jane Technologies, an online ordering platform service for cannabis retailers.
MediPharm Labs announced it has executed a supplementary agreement to its Asset Purchase Agreement with 1193269 B.C. Ltd. (o/a Shelter Cannabis) for the Shelter Cannabis Brands IP portfolio. This IP has been focused on Wildlife Cannabis domestic dry flower and pre-roll products that are manufactured and distributed via the MediPharm sites.
The Six Nations Cannabis Commission is calling out banks for refusing to provide bank accounts to Six Nations cannabis retailers after one of their member stores was robbed this week. They say this is a result of Ontario not recognizing Six Nations law.
In the first quarter of 2023, insurance reimbursements for medical cannabinoid products in Germany reached approximately 50.9 million euros. Dried-flower accounted for 21.1 million euros, while finished pharmaceutical products like Sativex and Epidolex recorded sales of 13.1 million euros. During the same quarter, Canada’s regulated cannabis market registered medical cannabis sales worth $98 million, reports Cannabis.net.
A story in the Japan Times looks at a trend of cannabis use among young people and the evolving attitudes towards cannabis in Japan.
A recent government analysis predicts that the Drug Enforcement Administration (DEA) will most likely reschedule marijuana following the recommendation of federal health authorities. The DEA affirmed to Congress in 2020 that it is required by law to give the Department of Health and Human Services (HSS) precedence on matters of science and health in a report released on Sept. 13 by the Congressional Research Service (CRS), a think tank for public policy run by the federal government.
Based on the analysis, it is unlikely that the federal drug policy will be advanced in a way that may be revolutionary.
This has far-reaching consequences not only for the U.S. cannabis industry but also for individuals who use marijuana and seek federal employment or assistance, including military service and access to public housing. Researchers point out that the DEA’s past responses in congressional hearings indicate its tendency to align with the FDA’s recommendations on scientific and medical matters. The CRS report further notes that there is no record of the DEA rejecting an FDA proposal for rescheduling.
HHS’s recommendation to shift cannabis from Schedule 1 to Schedule 3 under the Controlled Substances Act is a crucial part of the ongoing federal review of marijuana’s legal status initiated by President Joe Biden last October. The DEA’s current responsibility is to evaluate how this reclassification impacts legal and policy-related questions, including U.S. obligations under international drug-control treaties. Additionally, the agency must formulate an appropriate modification to federal law.
The review is anticipated to conclude by year-end, with potential changes to federal law occurring as early as next spring.
Although marijuana remains illegal at the federal level, 38 states have legalized it for medical purposes, while 23 states have legalized it for recreational use. Rescheduling the substance would have significant consequences for both the marijuana industry and cannabis users. For starters, the stringent tax code provision, Section 280E, which currently prevents cannabis businesses from claiming regular tax deductions on federal tax returns, would no longer be applicable.
Furthermore, medical cannabis users may experience fewer barriers to accessing public housing, obtaining immigrant visas, federal employment and firearm ownership.
Under the Controlled Substances Act (CSA), Schedule 1 contains substances with a high potential for abuse and minimal or no recognized medical utility. In stark contrast, Schedule 3 substances are accessible legally through a doctor’s prescription, following a rigorous FDA approval process. Such substances are also deemed to have a relatively lower potential for psychological and physical dependence.
As the federal restrictions on marijuana gradually ease, many companies are likely to mushroom in the industry, and ancillary companies such as Innovative Industrial Properties Inc. (NYSE: IIPR) that serve marijuana companies could see their operations grow faster.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
Life Cycle Botanics is a full-service commercial nursery serving the Canadian cannabis industry.
Utilizing a big picture, “holistic” approach to genetic selection and supply, Life Cycle launched in October 2021 and has quickly established itself as one of the most respected cannabis nurseries in Canada.
The partnership behind Life Cycle Botanics spans decades. Founders Mark Qvist, Shane Beltramo, and Jon Green’s history started in their high school days in BC and continued throughout the legacy years until they entered the legal market space in 2019. It was shortly thereafter that the longtime friends, (along with Mark’s wife Kim), formed Life Cycle Botanics on what they describe as a foundation of trust, friendship and loyalty.
Green is now the director of operations and responsible for overseeing the key assets of production and maintaining high quality, disease-and pest-free plants. Beltramo is the director of sales, coordinating the sales and marketing logistics and developing client relationships. Qvist acts as the CEO, driving business development, working on strategic planning, and looking for key market indicators to assist clients with market direction.
Life Cycle Botanics’ team focuses on not only producing high-quality cannabis clones for sale, but also working with cannabis producers to plan out what strains are most suitable for the grower and what future provincial market demand for different cultivars will be.
“This isn’t just one and you’re done. We’re not just selling a clone. We need our clients to do well; we need their weed to sell so that they continue to use our services. Our focus is on the long term and this is where we can really add value.”
Mark Qvist, Life Cycle Botanics
This is one of the unique approaches that sets the cannabis nursery apart from others in Canada, says Qvist. While many seek to provide growers with quality genetics for their facilities, the Qvists and their team are working hand-in-hand with their clients in a true clone-to-sale service, planning for everything from which cultivars will grow best under what kinds of conditions, to ensuring they aren’t flooding the market with one cultivar by providing it to multiple growers.
“This isn’t just one and you’re done. We’re not just selling a clone,” says Qvist. “We need our clients to do well; we need their weed to sell so that they continue to use our services. Our focus is on the long term and this is where we can really add value.”
This process isn’t easy, he explains. It means spending time growing out potential cultivars and learning as much as they can about the specific needs and traits of each variety, a process that can take years.
“The research we have to do is so extensive based on how genetics are reacting to all the different facilities, you know: the system, the lights, the mediums we’re using, the nutrients, the growers’ techniques even. Everything is so specific.
“When we do our R&D trials, we filter through so many genetics to find the ones that will check all the boxes, but that’s under one environment. Once it’s proven that we believe this is a very good genetic, we then work with some of our partners to test them in different environments to see what works best under what conditions.”
This process takes time, but allows Life Cycle to better identify which strains will grow well in what setting and assist the growers through all stages of growth. Since each cannabis cultivar will have unique attributes—nutrient, light, and environmental demands—this experience is another value-add the nursery brings to its clients.
“We’re always talking to the processors who are bringing these products to market. We’re finding out what the provinces will look for maybe six months from now. Every choice we make when it comes to selecting what we make available for growers is because we’re thinking about where the gaps in the market are instead of just selling everyone the same strain and saturating the market.”
Mark Qvist, Life Cycle Botanics
Another factor to consider when it comes to strain selection is working with processors and distribution boards to determine future product calls and how to meet them.
“A grower might have a strain they love growing. They might know how to grow it well, but if you can’t get the provinces to buy it, none of that matters,” explains Qvist. “We work with growers, especially micro cultivators, but we’re always talking to the processors who are bringing these products to market. We’re finding out what the provinces will look for maybe six months from now. Every choice we make when it comes to selecting what we make available for growers is because we’re thinking about where the gaps in the market are instead of just selling everyone the same strain and saturating the market.”
Another factor Qvist takes into account is the shelf life of the product. By growing out and testing every cultivar they offer, they can know what the flavour profile of the product will be over time.
“We know the timelines of getting product to market, so we filter out genetics that don’t have a shelf life to them. They can be phenomenal and hit all the points, but if they lose their flavour profile in a few months, then we know that isn’t going to work for a lot of our clients.”
New research has revealed that a single dose of psilocybin, the main psychoactive agent in psychedelic mushrooms, can boost neuroplasticity in users. Scientists found that the psychedelic was capable of inducing neural changes that were associated with reductions in depression symptoms.
Neuroplasticity refers to the brain and nervous system’s ability to change and adapt to interior or exterior stimuli by reorganizing neural connections, functions and structure. Researchers have been looking for ways to harness neuroplasticity and use it to treat mental disorders such as major depressive disorder (MDD) and addiction disorders. Psychedelics represent a new frontier in psychiatry that could finally allow scientists to leverage neuroplasticity and use the brain’s ability to adapt and evolve to supercharge mental-health treatments.
A flurry of studies has found that various psychedelics can provide long-term relief against mental disorders such as post-traumatic stress disorder, depression, anxiety and eating disorders. However, while scientists believe hallucinogens deliver their mental-health benefits by acting on neural receptors such as the serotonin 5-HT-2A receptor, we still don’t understand the exact biological mechanisms that allow psychedelics to offer mental health benefits.
Researchers from Northeastern University and Yale University School of Medicine set out to determine whether psychedelics treated mental disorders by inducing neuroplasticity. The study authors noted that it was especially important to understand the neural mechanisms that allowed psychedelics to induce long-term improvements in mood after minimal doses. The interinstitutional team of researchers used data collected from 22 individuals with MDD. With an average age of 20 years, the individuals in the participant pool had failed to respond to at least one depression treatment and stopped taking traditional antidepressants for at least two weeks prior to joining the study.
Participants were taken through two dosing sessions with a month interval between the dosing sessions, receiving a microcrystalline cellulose placebo during the first session and around 0.3-35 mg/kg of psilocybin during the second dosing session. Psychiatrists and study therapists guided the participants during the dosing sessions and provided psychotherapy before, during and after the guided sessions.
The research team used EEG (electroencephalography) and clinical assessments to analyze the effects of psilocybin and found that it caused “significant improvements” in depressive symptoms over time. Furthermore, the researchers discovered a substantial increase in a pattern of neural activity linked with neuroplasticity that suggests psychedelics may deliver some of their mental health benefits via neuroplasticity.
Study author and Yale University School of Medicine Albert E. Kent Endowed Professor of Psychiatry Deepak Cyril D’Souza said the team found evidence pointing to “enduring changes” in participants’ brains after a single psilocybin dose. Further research will be necessary to replicate the study on a larger scale and fully understand the biological mechanisms that allow psychedelics to induce enduring neural changes.
With companies such as Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) also engaged in developing therapeutic formulations from psychedelics, the public could soon have much more information about how these substances help to treat mental illnesses.
About PsychedelicNewsWire
PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
The event, whose hallmark is to bridge producers and retailers, left many with an optimistic takeaway at the end of two days at Exhibition Place.
Toronto’s now second Hall of Flowers, with its free-flowing exchanges both in conversation and product samples, kickstarted the Fall season with attendees leaving with bags brimming with colourful packs of innovative adult-use cannabis products – from infused maple candies, hash sodas, engraved vape pens and botanical blunt paper pre-rolls.
Exhibitors had this to say about the event:
Greg Pantelic, founder and CEO, AHLOT
“It’s been great – a good turnout, a good amount of retailers…We don’t do a lot of these industry events, but [Hall of Flowers] is one we go deep on.
Advertisement
“[Between 2018 and 2023], it’s night and day. It’s a lot more, I’ll say, competitive and saturated. That said, I think there are points of progress, there’s been progress over the years, but I think it’s still far from the progress we all hoped out the gate, but progress has been made, at least we’re able to give out samples; we’re able to show off product and get it in the hands of our customers.
“[We’re most excited about] continued growth in the industry. We’d love to see some maturation, would love to see some changes in policy to make it more commercially viable, some reforms in government around excise taxes, but all in all at the end of the day a lot of people sacrificed for us to have the opportunity to sell this product legally.”
Madison Trumble, Pax Vaporizer
“It’s been incredible! It’s been super busy. We had over 500 attendees yesterday, and 350 budtenders today, so it gives people a chance to connect with the cannabis community and share all the innovation that’s been going on.
“Even though it’s been [five years since legalization] the industry is still really young, there’s a lot of growth to be done, we’re still learning every day about consumer needs, about retail needs as well, and how we can better meet them in terms of product initiatives and promotions. So we’re learning a lot, but I think we’re heading in the right direction. I think it’s mostly positive and everyone is contributing in their own way.”
Product samples, Hall of Flowers, Toronto 2023.
This year’s event had many companies showing off all new ways consumers can enjoy cannabis. Matt Cherkas, co-founder of Sheesh Hash Soda products, was present to offer samples of his company’s new black cherry hash cola, infused with 10mg of THC.
Representatives of Zèle, a hand brewed cannabis-infused craft beverage brand, were also present to share the Edmonton company’s story.
Jonathan Martin, national brand manager, Bubble Bud Inc.
“It’s been a really great event for us just to be able to engage with retailers and honestly the community. As an Edmonton-based brand, we’re not getting out to Ontario as much, so to engage with the retailers, really get to know their teams from all the way from the inventory buyers to the budtenders, getting to present the brand to them but not have to travel between all the different locations from Edmonton to here. It’s a really great opportunity for us to showcase our product.”
Hall of Flowers proved the cannabis industry has much to be excited about. “Vice Papa” Max Benitah, and his team from Papa’s Herb were steadily handing out infused “blunts” made from chamomile leaves, for an alternative to traditional blunt papers.
Aurora proved there’s no such thing as too much THC with their new 50 per cent THC pre-rolls.
And Jen Meyers, founder and CEO of Manna, a producer of cannabis infused maple sugar candies, was present to offer an edible cognizant of the vast array of cannabis experiences consumers may be looking for.
Recent Comments